Cargando…
Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed d...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251772/ https://www.ncbi.nlm.nih.gov/pubmed/33078426 http://dx.doi.org/10.1002/hep.31601 |
_version_ | 1783717159048839168 |
---|---|
author | Starlinger, Patrick Pereyra, David Hackl, Hubert Ortmayr, Gregor Braunwarth, Eva Santol, Jonas Najarnia, Sina Driedger, Michael R. Gregory, Lindsey Alva‐Ruiz, Roberto Glasgow, Amy Assinger, Alice Nagorney, David M. Habermann, Elizabeth B. Staetttner, Stefan Cleary, Sean P. Smoot, Rory L. Gruenberger, Thomas |
author_facet | Starlinger, Patrick Pereyra, David Hackl, Hubert Ortmayr, Gregor Braunwarth, Eva Santol, Jonas Najarnia, Sina Driedger, Michael R. Gregory, Lindsey Alva‐Ruiz, Roberto Glasgow, Amy Assinger, Alice Nagorney, David M. Habermann, Elizabeth B. Staetttner, Stefan Cleary, Sean P. Smoot, Rory L. Gruenberger, Thomas |
author_sort | Starlinger, Patrick |
collection | PubMed |
description | BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed drugs in the United States and Europe and given serotonin’s impact on liver regeneration, we evaluated whether perioperative use of SSRIs/SNRIs affects outcome after hepatic resection. APPROACH AND RESULTS: Consecutive patients undergoing hepatic resection (n = 754) were retrospectively included from prospectively maintained databases from two European institutions. Further, an independent cohort of 495 patients from the United States was assessed to validate our exploratory findings. Perioperative intake of SSRIs/SNRIs was recorded, and patients were followed up for postoperative liver dysfunction (LD), morbidity, and mortality. Perioperative intraplatelet serotonin levels were significantly decreased in patients receiving SSRI/SNRI treatment. Patients treated with SSRIs/SNRIs showed a higher incidence of morbidity, severe morbidity, LD, and LD requiring intervention. Associations were confirmed in the independent validation cohort. Combined cohorts documented a significant increase in deleterious postoperative outcome (morbidity odds ratio [OR], 1.56; 95% confidence interval [CI], 1.07‐2.31; severe morbidity OR, 1.86; 95% CI, 1.22‐2.79; LD OR, 1.96; 95% CI, 1.23‐3.06; LD requiring intervention OR, 2.22; 95% CI, 1.03‐4.36). Further, multivariable analysis confirmed the independent association of SSRIs/SNRIs with postoperative LD, which was closely associated with postoperative 90‐day mortality and 1‐year overall survival. CONCLUSIONS: We observed a significant association of perioperative SSRI/SNRI intake with adverse postoperative outcome after hepatic resection. This indicates that SSRIs/SNRIs should be avoided perioperatively in patients undergoing hepatic resections. |
format | Online Article Text |
id | pubmed-8251772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82517722021-07-07 Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery Starlinger, Patrick Pereyra, David Hackl, Hubert Ortmayr, Gregor Braunwarth, Eva Santol, Jonas Najarnia, Sina Driedger, Michael R. Gregory, Lindsey Alva‐Ruiz, Roberto Glasgow, Amy Assinger, Alice Nagorney, David M. Habermann, Elizabeth B. Staetttner, Stefan Cleary, Sean P. Smoot, Rory L. Gruenberger, Thomas Hepatology Original Articles BACKGROUND AND AIMS: Platelet‐stored serotonin critically affects liver regeneration in mice and humans. Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs) reduce intraplatelet serotonin. As SSRIs/SNRIs are now one of the most commonly prescribed drugs in the United States and Europe and given serotonin’s impact on liver regeneration, we evaluated whether perioperative use of SSRIs/SNRIs affects outcome after hepatic resection. APPROACH AND RESULTS: Consecutive patients undergoing hepatic resection (n = 754) were retrospectively included from prospectively maintained databases from two European institutions. Further, an independent cohort of 495 patients from the United States was assessed to validate our exploratory findings. Perioperative intake of SSRIs/SNRIs was recorded, and patients were followed up for postoperative liver dysfunction (LD), morbidity, and mortality. Perioperative intraplatelet serotonin levels were significantly decreased in patients receiving SSRI/SNRI treatment. Patients treated with SSRIs/SNRIs showed a higher incidence of morbidity, severe morbidity, LD, and LD requiring intervention. Associations were confirmed in the independent validation cohort. Combined cohorts documented a significant increase in deleterious postoperative outcome (morbidity odds ratio [OR], 1.56; 95% confidence interval [CI], 1.07‐2.31; severe morbidity OR, 1.86; 95% CI, 1.22‐2.79; LD OR, 1.96; 95% CI, 1.23‐3.06; LD requiring intervention OR, 2.22; 95% CI, 1.03‐4.36). Further, multivariable analysis confirmed the independent association of SSRIs/SNRIs with postoperative LD, which was closely associated with postoperative 90‐day mortality and 1‐year overall survival. CONCLUSIONS: We observed a significant association of perioperative SSRI/SNRI intake with adverse postoperative outcome after hepatic resection. This indicates that SSRIs/SNRIs should be avoided perioperatively in patients undergoing hepatic resections. John Wiley and Sons Inc. 2021-03-16 2021-05 /pmc/articles/PMC8251772/ /pubmed/33078426 http://dx.doi.org/10.1002/hep.31601 Text en © 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Starlinger, Patrick Pereyra, David Hackl, Hubert Ortmayr, Gregor Braunwarth, Eva Santol, Jonas Najarnia, Sina Driedger, Michael R. Gregory, Lindsey Alva‐Ruiz, Roberto Glasgow, Amy Assinger, Alice Nagorney, David M. Habermann, Elizabeth B. Staetttner, Stefan Cleary, Sean P. Smoot, Rory L. Gruenberger, Thomas Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title | Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title_full | Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title_fullStr | Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title_full_unstemmed | Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title_short | Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery |
title_sort | consequences of perioperative serotonin reuptake inhibitor treatment during hepatic surgery |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251772/ https://www.ncbi.nlm.nih.gov/pubmed/33078426 http://dx.doi.org/10.1002/hep.31601 |
work_keys_str_mv | AT starlingerpatrick consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT pereyradavid consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT hacklhubert consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT ortmayrgregor consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT braunwartheva consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT santoljonas consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT najarniasina consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT driedgermichaelr consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT gregorylindsey consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT alvaruizroberto consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT glasgowamy consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT assingeralice consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT nagorneydavidm consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT habermannelizabethb consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT staetttnerstefan consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT clearyseanp consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT smootroryl consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery AT gruenbergerthomas consequencesofperioperativeserotoninreuptakeinhibitortreatmentduringhepaticsurgery |